<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544294</url>
  </required_header>
  <id_info>
    <org_study_id>RAIN</org_study_id>
    <nct_id>NCT03544294</nct_id>
  </id_info>
  <brief_title>veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study</brief_title>
  <acronym>RAIN</acronym>
  <official_title>veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      For permanent coronary stents, reduction of thickness of struts have become one of the most
      important innovation, being related to easier manipulation, reduced risk of stent thrombosis
      and low rate of revascularization. Consequently the investigators performed a multicenter
      registry enrolling all consecutive patients treated with very thin stents for ULM or
      bifurcation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For permanent coronary stents, reduction of thickness of struts have become one of the most
      important innovation, being related to easier manipulation, reduced risk of stent thrombosis
      and low rate of revascularization. Previous studies do not have enough power to detect
      potential significant difference for ULM or bifurcation lesions. Consequently the
      investigators performed a multicenter registry enrolling all consecutive patients treated
      with Biomatrix Flex, Xience Alpine, Ultimaster, Resolute Onyx and Synergy. MACE (a composite
      end point of death, myocardial infarction, target lesion revascularization and stent
      thrombosis) will be the primary end point, while its single components will be the secondary
      ones.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>Major Adverse Cardiac Events (MACE) is a composite end-point which includes: death for any cause; non fatal myocardial infarction; target lesion revascularization (TLR); in-stent thrombosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators defined Target Lesion Revascularization as either repeat percutaneous or surgical revascularization for a lesion anywhere within the stent or the 5-mm borders proximal or distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>Death for any cause (both cardiologic and non-cardiologic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non fatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>non fatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>TVR is defined as any repeat PCI in the target vessel indicating the disease progression.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2800</enrollment>
  <condition>Stent Restenosis</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Left Main Coronary Artery Disease</condition>
  <condition>Coronary Bifurcations</condition>
  <condition>Very Thin Stents</condition>
  <arm_group>
    <arm_group_label>Group</arm_group_label>
    <description>Consecutive patients treated with very thin stents on ULM and bifurcation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience alpine, ultimaster, resolute onyx, synergy</intervention_name>
    <description>PCI will be performed</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients undergoing PCI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing PCI on unprotected left main or coronary bifurcation

        Exclusion Criteria:

          -  PCI performed on other coronary vessels
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Citta della Salute</name>
      <address>
        <city>Turin</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Fabrizio D'Ascenzo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

